Long-term evaluation of cellular immunity during antiretroviral therapy and immunization with human immunodeficiency virus type 1 (HIV-1) Env glycoprotein in HIV-1-infected persons

Journal of Infectious Diseases

Volumn 176, Issue 4, 1997, Pages 904-912

  Carlesimo, Maurizio ^d   Pontesilli, Oscar ^b   Guerra, Emma C ^c   Varani, Anna R ^d   Bernardi, M Livia ^d   Ricci, Giovanni ^d   Alario, Cecilia ^d   Pirillo, Maria F ^d   Mattiacci, Graziella ^d   Leone, Patrizia ^d   Cassone, Antonio ^d   Aiuti, Fernando ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CENTRAL LABORATORY   (Netherlands)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; GLYCOPROTEIN GP 160;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VACCINATION; VIRUS INFECTION;

EID: 16944364181     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516500     Document Type: Article

References (14)

1. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature 1987;327:473-6.
2. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-4.
3. Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993; 328:327-35.
4. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. J Clin Invest 1989; 84:1892-9.
5. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic milliliter. N Engl J Med 1990;322:941-9.
6. Staszewski S. Zidovudine and lamivudine: results of phase III studies. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(suppl I):S57.
7. Redfield RR, Birx DL, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gpl60 in patients with early human immunodeficiency virus infection. N Engl J Med 1991:324:1677-84.
8. 3 CD4 T lymphocytes. J Infect Dis 1996; 173:1336-46.
9. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1993;41:1-119.
10. Guerra E, Ricci G, Carlesimo M, et al. Immunological aspects of patients with HIV-1 disease following immunization with recombinant gp160 (VaxSyn). Antibiot Chemother 1996;48:147-54.
11. Quinti I, Palma C, Guerra EC, et al. Proliferative and cytotoxic responses to mannoproteins of Candida albicans by peripheral blood lymphocytes of HIV-infected patients. Clin Exp Immunol 1991;85:485-92.
12. Pontesilli O, Carlesimo M, Varani AR, et al. HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals. Clin Exp Immunol 1995;100:419-24.
13. Schrier RD, Gnann JW, Landes R, et al. T cell recognition of HIV synthetic peptides in a natural infection. J Immunol 1989; 142:1166-76.
14. Pontesilli O, Varani AR, Carlesimo M, et al. HIV-Env specific cytotoxicity in patients with asymptomatic HIV disease before and after immunization with recombinant gp160. Int J Immunopathol Pharmacol 1994; 7: 251-60.